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ABSTRACT 
Background 
In 2010, 2.2 million adolescents were living with HIV (Human Immunodeficiency Virus) 
worldwide. This study aimed to describe the socio-demographic and clinical characteristics of 
the adolescents (10-19 years old) initiating anti-retroviral treatment (ART) and to investigate 
characteristics that are associated with virological failure in adolescents on ART.  
Methods 
This was an analysis of adolescents initiating ART from June 2004-2010 at the Hlabisa 
Treatment and Care Programme in KwaZulu-Natal, South Africa. Data was collected from 
two datasets at Africa Centre for Health and Population Studies. Time to outcomes of death 
and lost to follow up (LTFU) were quantified using Kaplan-Meier estimates. The outcome 
was virologic response (< 70copies/ml) after at least 6 months on ART and the associations 
with an unsuppressed viral load were investigated using multivariable logistic regression. 
Results 
543 adolescents, median age 15 years (IQR 12-18), initiated ART; 67.8% (368) were 
females. Age at treatment initiation showed a bimodal distribution, with a peak at 11 years 
and another at 17-19 years; 61 females aged 16-19 years initiated ART whilst pregnant. At 
baseline, median CD4 count was 152 cells/µl (IQR 72-251), 392 (72.2%) had prior TB and 
129 (23.8%) a weight-for-age z-score ≤ -2 (i.e. were under-nourished). Numbers of 
adolescents starting ART increased from 53 in the years 2004-2006 to 196 in 2010. Overall 
mortality was 36.5 per 1000 person years (95% CI 27.2 - 48.8); LTFU 98.8 per1000 person 
years (95% CI 82.8-118). Adjusting for age and gender, LTFU was significantly higher in 
females initiating in late adolescence (15-19 years) (p<0.001) and 24 (39.3%) of those 
v 
 
initiating ART whilst pregnant were LTFU. The first viral load after initiation was taken at a 
median time of 11.25 months (IQR 7.78-16.20). Of the 364 adolescents with a viral load 
result after at least 6 months of ART, 119 (32.7%) had an unsuppressed viral load (95% CI 
27.9- 37.5). Adolescents who initiated in the year 2010 were found to have less odds of an 
unsuppressed viral load compared to those who initiated between 2004 and 2006 [adjusted 
Odds Ratio (aOR) 0.29 (95% CI 0.11-0.79)]. Those who had the first viral load test done after 
> 30 months of ART had higher odds of an unsuppressed viral load compared to those tested 
after 6-12 months of ART [ aOR 6.88 (95% CI 1.29-36.66)].  
Conclusion 
Despite the yearly increase in adolescents initiating ART, good virological responses can be 
obtained through increased ART support to both individuals and health care providers. 
Timely viral load monitoring identifies those in need of increased adherence support on ART 
and may result in good virological responses.   
Recommendations 
Adolescents on ART are a vulnerable group that requires special attention to improve clinical 
and virological outcomes. Adolescent friendly ART clinics may be useful in providing this 
service and mitigate the high attrition rates of those on treatment for HIV. Public health 
awareness campaigns on HIV and its treatment may have a positive impact on virological 
response to ART and therefore campaigns targeting adolescents must be intensified. Early 
virological testing after 6 months on ART to monitor treatment responses helps to identify 
those with sub-optimal response to ART and reduce the progression to virological failure and 
drug resistance to anti-retroviral drugs. 
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CHAPTER 1: INTRODUCTION 
The chapter begins with an overview of the Human Immunodeficiency Virus (HIV) disease 
burden in the world, sub-Saharan Africa (SSA) and South Africa. The impact of virological 
failure on both an individual’s HIV treatment and public health HIV programmes are 
highlighted.  Reasons that make the adolescents on antiretroviral treatment (ART) an 
important group for research are explored and this is followed by a review of the published 
literature on virological failure on ART. The chapter ends with a description of the objectives 
of the study.  
1.1 Background 
The HIV pandemic has entered its third decade with little prospect of a cure [1, 2]. By the end 
of 2010, an estimated 34 million people were infected with HIV worldwide, an increase of 
17% from 2001 [3]. This has resulted in an increased need for, and uptake of, HIV treatment. 
In low and middle income countries, 47% of the 14.2 million people eligible for treatment 
were on ART at the end of 2010 (CD4 ≤ 200), compared to 39% at the end of 2009 [3]. The 
World Health Organization (WHO) defines an adolescent as an individual between the ages 
of 10-19 years inclusive [4] and this is the definition used in this report. In 2010, 2.2 million 
(2.0-2.5 million) adolescents were living with HIV worldwide and 60% (1.3 million) were 
females [5]. 
SSA, a region that  has 12% of the global population, has the greatest burden of HIV (68% 
worldwide in 2010) and it remains the epicentre of the pandemic [3]. In 2010, there were an 
estimated 1.87 million adolescents infected with HIV in SSA (85% worldwide) [5].  
In 2010, an estimated 5.6 million South Africans were living with HIV of whom 280 000 
were children aged between 0 and 14 years. South Africa had an overall HIV prevalence of 
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17.9% in 2010 [3, 6, 7] and the prevalence amongst those aged 15-19 years was 7% and 3% 
in females and males respectively [5]. There is variation in the prevalence of HIV in the 
provinces of South Africa with KwaZulu-Natal having the highest disease burden with an 
estimated 39.5% among antenatal clinic attendees in 2010 [8]. The prevalence amongst those 
aged 15-19 years was 20.5% in this province as estimated in the same survey [8]. According 
to the KwaZulu-Natal Department of Health (DOH), overall ART coverage in the province 
was 81% between 2010 and 2011 [9]. 
The study setting is the Africa Centre for Health and Population Studies (AC) which is based 
in the Hlabisa sub-district of the Umkhanyakude district of KwaZulu-Natal 
(www.africacentre.com). Since 2000, the AC has collected data twice-yearly through 
interviews with key-household informants and annual household socio-economic surveys in 
its 438 square kilometre Demographic Surveillance Area (DSA) which is home to 85 000 
individuals. The DSA is within the Hlabisa sub-district. The area has a high disease burden of 
HIV with an imputed based prevalence estimate of 27.3% in 2011 [10]. The overall HIV 
incidence in the area was 3.4 per 100 person-years (95% CI 3.1-3.7) with no sign of decline 
between 2003 and 2007 [11]. In 2004, as a response to the Comprehensive HIV and AIDS 
Care Management and Treatment Plan, the AC partnered with the DOH to initiate the Hlabisa 
HIV Treatment and Care Programme [12]. The programme was funded from 1 August 2004 
to 31 December 2006 by the Elizabeth Glaser Paediatric AIDS Foundation (EGPAF) and 
since 1 May 2005 by the President’s Emergency Plan for AIDS Relief (PEPFAR) and United 
States Agency for International Development (USAID) [12]. Between June 2004 and July 
2011, a total of 667 adolescents were initiated on ART (personal communication senior 
database scientist, Africa Centre) [13].  
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WHO recommends that suppressed plasma viral loads should be reached within the first 6 
months of ART [14]. Virological failure is defined by the South African DOH as two 
consecutive viral loads >1000 copies/ml at least 3 months apart after having been on ART for 
at least 6 months [15]. Though the DOH recommends using 1000 copies/ml as the threshold 
to determine if viral loads are suppressed, the Hlabisa HIV Treatment and Care programme 
used lower thresholds (25 copies/ml, 40 copies/ml and 70 copies/ml) during the study period.  
This was due to the different laboratory viral load test kits with different undetectable 
thresholds that were used. The DOH recommends viral load monitoring of individuals who 
have initiated ART after 6 months, 12 months and yearly thereafter if viral load is 
suppressed. After 6 months on treatment, a raised viral load indicates poor response to 
treatment and is used to identify individuals who need intense adherence counselling. For 
these individuals, a second test is done after 3 months to reassess virological suppression 
[15].  
Due to the lack of the second viral load used to ascertain virological failure, the outcome in 
this study was an unsuppressed viral load to assess response to ART after at least 6 months of 
treatment. This study used the highest of the viral load thresholds at the Hlabisa HIV 
Treatment and Care programme (70 copies/ml) to determine if individuals had a suppressed 
viral load or not. 
1.2 Statement of the Problem 
With the expansion of ART programmes and coverage, monitoring of individuals on ART 
poses a great challenge in the public sector where there are resource limitations, particularly 
healthcare worker shortages [16, 17]. As survival on treatment has increased and HIV has 
become a chronic disease, ART demands good adherence to achieve long term virological 
suppression which is key to minimising drug resistance and preventing treatment failure [14, 
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18, 19]. With high patient to health caregiver ratios, an increased number of individuals are 
likely to have ART failure as monitoring of those on treatment becomes less intense. After 
treatment failure, an individual needs to switch to another ART regimen [15]. In resource-
limited settings where genotyping for HIV drug resistance is unaffordable, switching to 
another ART regimen is done without distinguishing if failure is due to poor adherence alone 
or to drug resistance. The human and financial implications of ART failure are significant 
with the average annual cost of alternate ART regimens reaching up to eight times that of a 
first-line ART regimen [14]. The regimens may be more complex and more difficult to take 
than the initial treatment combinations. In resource-limited settings, second line treatment 
may not be available resulting in an increase in HIV morbidity and mortality [14, 20]. 
Adolescents on ART face many challenges related to treatment adherence, which will be 
discussed below, hence the importance of describing the factors associated with virological 
failure in this age group to identify potential cases of treatment failure. This will also aid 
healthcare workers in the early identification of those requiring intense adherence support 
with the aim of reducing those requiring treatment regimen switches.   
1.3 Justification 
Poor adherence to treatment regimens is the most common cause of detectable plasma viral 
loads in individuals after 6 months of ART initiation [21]. This is due to suboptimal viral 
suppression by insufficient plasma anti-retroviral drug levels [14]. Reinforcing the 
importance of adherence is vital in improving long-term ART outcomes. Research in 
southern Africa using pharmacy refills as an outcome measure, suggests that adolescents (11-
19 years old) may have less adherence to ART compared to adults aged over 20 years (20.7% 
and 40.5% after 6 months of ART respectively; p< 0.01) [22].  
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Adolescence is a challenging period in which the individual undergoes physiological and 
psychological changes characterized by exceptionally rapid growth and development leading 
to puberty and sexual development [23]. Adolescents can be grouped according to their 
stages of development into early (10-14 years) and late (15-19 years) adolescence [23, 24]. 
Compared to those who are HIV negative, adolescents on ART have an extra burden of being 
on daily lifelong treatment. During adolescence, an individual’s capacity for abstract and 
critical thinking also develops [23, 24] and those with HIV may have cognitive impairment 
and mental health problems such as anxiety, depression, attention-deficit or hyperactivity 
disorder and post-traumatic stress disorder [25]. The stigma of living with HIV, especially 
from peers who are not mature enough to understand, has a strong impact on the 
psychological and emotional development of HIV positive adolescents [26, 27]. As social 
relationships become more important, peer pressure may result in risky behaviour and hence 
adherence on treatment may reduce [27, 28]. Koenig et al reported that three behavioural 
health challenges are associated with adolescents on ART: a decreased adherence to 
treatment; earlier sexual debut and accompanying pregnancy and transmission risk; mental 
health problems [28]. All these challenges may have a negative impact on adherence to ART 
leading to treatment failure; identifying early warning predictors of failure in this group is 
therefore extremely important. 
Literature on the factors associated with treatment failure in adolescents on ART is sparse 
even though they are a vulnerable group. A search in the PubMed database on the factors 
associated with virological failure in adolescents on ART, retrieved only 8 articles. With 
ART increasing the survival of HIV-positive individuals and HIV now a chronic disease, an 
increased number of children are surviving into adolescence emphasising the need for more 
research in this group to improve their quality of life and adherence to drugs [18, 19].  
6 
 
With the United Nations Millennium Development Goal number 6 of combating HIV by 
2015 [29] , adolescent monitoring for early warning signs of failure should be intensified to 
prevent drug resistance to anti-retroviral drugs [14]. This report adds to the knowledge base 
of the management of adolescents on ART in public health HIV programmes in rural South 
Africa. 
1.4 Literature Review 
1.4.1 Characteristics of adolescents initiating ART     
In a study in Cape Town analysing the treatment outcomes of adolescents (9-19 years of age) 
between 2002 and 2009, the median age at ART initiation was 11.5 years (IQR 10.0-17.3) 
[30]. Of those initiating ART, 67.7% were in early adolescence, 12.3% in middle adolescence 
and 20.3% in late adolescence [30]. In a study analysing pooled data from nine countries in 
southern Africa in the Aid for AIDS treatment programme, the median age at initiation of 
non-perinatally infected adolescents was 16.4 years (IQR 11.9-18.8) [22]. The majority of 
individuals who initiated ART in the Hlabisa HIV treatment and Care Programme between 
2004 and 2008 were females (73%) [12]. This was the same for adolescents initiating in other 
programmes, Cape Town (66.2%) and southern Africa (72.7%) and their baseline median 
CD4 cell counts were 134 (IQR 41-198) and 144 (27-246) respectively [22, 30]. The median 
change in CD4 cell count from baseline to week 32 was 195 (IQR 136-439). Mortality rates 
for adolescents initiating ART were 2.9 per 100 person years (95% CI 2.3-3.7) and 5% for 
the programme in Cape Town and Aids for AIDS respectively [22, 30]. LTFU of adolescents 
in the Cape Town programme was 10 per 100 person years (95% CI 8.8-11.4) [22]. 
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1.4.2 Virological criteria as a measure of treatment failure  
There is no standard definition of ART failure but it can be defined by clinical, 
immunological or virological criteria. Immunological and clinical criteria are more 
appropriate for ruling out than for confirming virological failure. Immunological criteria have 
low sensitivity and positive predictive values (17.1% (95% CI 6.6–33.6%)) and (9.5% (95% 
CI 3.6–19.6%)) respectively compared to virological criteria [31, 32]. Due to this poor 
correlation between immunologic and virologic criteria, treatment failure may remain 
unnoticed in settings where HIV-RNA testing is not available for monitoring. A comparison 
of outcomes of ART in South Africa, where viral load monitoring is routine, with those in 
Malawi and Zambia, where monitoring is based on CD4 cell counts showed that the risk for 
death after 3 years of follow up (after adjusting for age, sex, first-line regimen and CD4 cell 
count) was 42% lower in South Africa (95% CI 0.50-0.66) [33]. Explanations of this finding 
may include the availability of viral load monitoring in South Africa resulting in early 
detection of failure, adherence counselling and timely switching of treatment regimens [33].  
1.4.3 Virological failure at ART programmes 
One viral load is used to determine viral suppression for individuals on ART [22, 34-37]. 
When two consecutive viral loads are available, virological failure can be concluded [15, 30]. 
A report on the outcomes of children ≤ 15 years old initiating ART between 2004 and 2008 
in the Hlabisa HIV treatment and care programme in KwaZulu-Natal  reported a 73.5% viral 
suppression (<25 copies/ml) after 6-12 months on ART [34].  
Another  study in Cape Town analysing treatment outcomes of adolescents (9-19 years of 
age) initiating ART, reported 27.5% viral suppression (<400 copies/ml) at 32 weeks of ART 
(p<0.001) [30]. The same study found a rate of virological failure of 8.2% (95% CI 4.6- 14.4) 
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when using an outcome of two consecutive viral load > 1000 copies/ml after 48 weeks of 
ART [30].  
An observational cohort study in nine southern African countries reporting viral suppression 
(≤ 400 copies/ml) for adolescents (11-19 years old) initiating ART between 1999 and 2006 
found a viral suppression rate of 63% after at least 6 months of treatment [22]. 
The IeDEA Southern Africa Collaboration analysed pooled data from children in 7 South 
African treatment programmes using an outcome of two consecutive unsuppressed viral loads 
with the second being > 1000 copies/ml, after 24 weeks of therapy. The objective of the study 
was to evaluate the probability of virological failure in children less than 16 years of age who 
initiated treatment between June 1999 and February 2008. Results showed that the 3 year 
probability for failure was 19.3% (95% CI 17.6%-21.1%) [38].  
The Peadiatric AIDS Clinical Trials Group 381 (PACTG) was an observational cohort study 
of 120 adolescents (11-22 years old) on ART between March 1999 and October 2001 at 28 
sites in the United States of America (USA). It reported that 59% of the cohort had achieved 
virological suppression (< 400 copies/ml) at week 16-24 of ART [37]. 
1.4.4 Factors associated with virological failure 
Factors associated with virological failure in adolescents have been investigated in a few 
studies including data from PACTG that was analysed at 24 weeks [39] and then at 60 weeks 
[37]. At 24 weeks, logistic regression was used to analyse the predictors of virological failure 
and neither immunologic nor demographic characteristics were found to be predictors, only 
adherence to ART influenced virological outcomes (p<0.001) [39]. At week 60, analysis was 
done using Cox proportional hazards models and only immunological factors (T cell markers) 
and adherence  were shown to be associated failure [37]. 
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The Reaching for Excellence in Adolescent Care and Health (REACH) project was an 
observational study  in the USA that analysed predictors of sub-optimal virological response 
in 154 adolescents (12-19 years old) initiating ART between 1996 and 2000 at 16 academic 
medical centres [40]. After at least 12 months on treatment, predictors of sub-optimal 
virologic response were adequate ART adherence (odds ratio (OR) 0.40 (95% CI 0.2-1.0)) 
and a history of prior ART use (i.e. prior use of single or dual ARV drugs before using a 
triple combination) (OR 2.90 (95% CI 1.10-5.70)) [40].  
These studies on adolescents had small sample sizes and therefore might have low statistical 
power. This may explain the lack of significant predictors compared with studies in adults 
and children. Table 1 below summarises some of the factors associated with virological 
failure found in studies conducted in adults and children.  
Some studies have shown an association between the age of ART initiation and virological 
failure [41-44]. An adult cohort study  in Europe with 52 clinical centres reported that the risk 
of failure reduced 14% with each one year increase of age (p=0.04) [42]. Children (0-18 
years of age) who initiated ART in Uganda and were followed up from April 2004 to June 
2005 showed that males had more than twice the odds of virological failure compared to 
females (95% CI 1.20-4.93) [41]. Adherence on treatment may increase with age [22] 
resulting in better virological outcomes.    
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Table 1: Factors associated with virological failure in adults and children in the 
literature 
Factors Association with virological failure Reference and country of study 
population 
Baseline age Children ≤ 18 years have increased risk 
for failure compared to those aged more 
than 18 years 
Kamya et al., 2007 (Uganda) [41] 
Paredes et al., 2000 (Europe) [42] 
Parienti et al., 2004 (France) [43] 
Tuboi et al., 2005 (Brazil) [44] 
Gender Males had higher odds for failure 
compared to females 
Kamya et al., 2007 (Uganda) [41] 
Baseline CD4 
count 
Baseline CD4 counts less than 50 cells/ 
µl have increased risk for failure 
compared to those greater than 150 
cells/µl  
Datay et al., 2010 (South Africa) [45] 
Kamya et al., 2007 (Uganda) [41] 
Paredes et al., 2000 (Europe) [42] 
Tuboi et al., 2005 (Brazil) [44] 
Baseline viral load One log increase of viral load increased 
the risk for failure 
Paredes et al., 2000 (Europe) [42] 
Tuboi et al., 2005 (Brazil) [44] 
Davies et al.,2011 (South Africa) [38] 
Orphans at 
baseline 
Those with no parents had higher risks 
of failure compared to those with at 
least one parent 
Janseens et al.,2007 (Cambodia) [46] 
Baseline treatment 
regimen 
Both Nevirapine and Ritonavir (as a 
single drug) based regimes had 
increased risk for failure compared to 
Efavirenz based regimes 
Davies et al.,2011 (South Africa) [38] 
Datay et al., 2010 (South Africa) [45] 
Kamya et al., (Uganda) [41] 
Exposure to 
prevention of 
mother to child 
transmission 
regimens 
Those exposed to at least one drug at 
PMTCT increased risk for failure than 
those who were not exposed 
Davies et al.,2011(South Africa) [38] 
Baseline 
Haemoglobin 
Baseline MCV 
No significant association with failure  Kamya et al., 2007 (Uganda) [41] 
Baseline Weight  No significant association with failure Davies et al.,2011 (South Africa) [38] 
Baseline WHO 
stage  
No significant association with failure Davies et al.,2011 (South Africa) [38] 
 
Baseline CD4 counts have been investigated as factors associated with treatment failure and 
some studies have shown that lower baseline CD4 counts have increased risk for failure [41, 
42, 44, 45]. A case-control study in the Western Cape of South Africa reported that an 
individual with a baseline CD4 count less than 50 cells/µl was six times more likely to have 
virological failure compared to those with a baseline CD4 count of more than 150 cells/µl 
(95% CI  2.3-18.8) [45]. Though there have been debates whether the baseline CD4 count can 
11 
 
be predictive of disease progression, those who initiate with lower CD4 counts are more 
immunocompromised and might have more opportunistic infections and are sicker hence 
adherence to ART may be less.  
The EuroSIDA study in Europe reported that having a higher baseline viral load was 
marginally significant in predicting virological failure. With every log increase in baseline 
viral load the risk of failing increased by 18% (95% CI 0.99-1.40) [42]. Higher levels of 
baseline viral loads have been shown to be predictive of disease progression [47] and may 
result in poorer treatment outcomes. Other baseline laboratory tests such as Haemoglobin and 
Mean Corpuscular Volume (MCV) have not been shown to have a significant association 
with failure [41]. 
The associations between drug regimens at initiation of treatment and virological failure have 
been explored. Initiating treatment with a Nevirapine (NVP) based versus an Efavirenz 
(EFV) based treatment regime was shown to be associated with virological failure (OR 2.46 
(95% CI 1.23-4.90)) in Uganda [41]. In the IeDEA study, NVP based and Ritonivar (RTV) 
(alone) based regimens had significant increased risks for failure compared to EFV based 
regimens (HR 1.77 (95% CI 1.11-2.83), HR 2.39 (95% CI 1.57- 3.64) respectively) [38]. This 
analysis also reported that the children exposed to Prevention of Mother to Child 
Transmission (PMTCT) drug regimens had a 40% increased risk for failure as compared to 
those who were not exposed (95% CI 1.02 to 1.92) [38]. Regimens that were used for the 
PMTCT include single dose NVP alone or in combination with Zidovudine (AZT) from 34 
weeks gestation [38]. NVP has been used widely as a single dose in PMTCT and NVP 
resistance may result in the poor virological responses in those who initiate on an ART 
combination that includes this drug.  
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A “drug holiday” of greater than 48 hours as a measure of adherence to treatment was 
evaluated in 71 HIV infected adults greater than 18 years in a cohort study in France (1996-
1997); virological failure was associated with repeated drug holidays (HR 3.3 (95% CI 1.3–
8.3)). The study also concluded that depression was an important predictor of failure (HR 2.5 
(95% CI 1.0–6.4)) [43]. Poor adherence results in suboptimal viral suppression resulting in 
poor virological outcomes [22]. 
In a study at a resource limited setting in Cambodia including 212 children less than 13 years, 
being an orphan had 3.8 times more risk of virological failure (95% CI 1.80–8.00) compared 
to those with at least one parent [46]. Orphaned children may have poor adherence support 
leading to a higher risk of treatment failure. 
Factors which have not been found to be associated with virological failure include weight at 
initiation, WHO stage at initiation (1/2 vs. 3/4) and year of initiation (before 2005 as 
compared to after 2005) [38].  
Predictors of virological failure can be modelled to develop a simple prognostic tool which 
uses scores to identify patients at increased risk of virologic failure. A model was derived 
from data obtained at Massachusetts General Hospital USA from patients who were 
virologically suppressed (viral load ≤ 400 copies/ml) on ART during the period 1 January 
2005 to 31 December 2006. Multivariable logistic regression was used to derive a one year 
failure predictive rule. A risk score based on seven predictors was used; suboptimal 
adherence, CD4 cell count < 100 cells/µl, drug and/or alcohol abuse, highly ART 
experienced, missed ≥ 1 appointment, prior virologic failure and virologically suppressed for 
≤ 12 months. The model was validated at Brigham and Women's Hospital and showed good 
discrimination (C statistic, 0.79) and calibration (chi (2) = 1.9, p= 0.93). It was concluded that 
the model could be used as an intervention to improve outcomes in ART management [48]. 
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1.4.5 Conclusion 
Treatment failure on ART is best determined by using virological criteria. The rates of 
virological failure in adolescents differ in ART programmes. Factors that are associated with 
virological failure in adolescents in the USA were adherence, a history of prior ART use and 
T cell markers. The baseline factors that are associated with virological failure in children 
and adults include age, gender, CD4 count, viral load, initial treatment combination, poor 
treatment adherence and being an orphan. Factors associated with virological failure can be 
used to develop prognostic tools to identify adolescents at high risk of treatment failure.  
This study seeks to investigate the factors associated with virological failure in adolescents in 
a nurse and counsellor-led rural ART programme in KwaZulu-Natal.  
1.5 Objectives 
1.5.1 Main Objective 
To describe and investigate the characteristics associated with virological failure(using an 
unsuppressed viral load as proxy) in adolescents (individuals aged 10-19 years inclusive) who 
initiated ART between June 2004 and December 2010 in the Hlabisa HIV Treatment and 
Care Programme, KwaZulu-Natal, South Africa. 
1.5.2 Specific Objectives 
1. To describe the clinical and socio-demographic characteristics of those who initiated 
ART as adolescents. 
2. To determine the prevalence of virological failure (using an unsuppressed viral load 
as proxy) after 6 months on ART in those who initiated treatment as adolescents. 
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3. To investigate the clinical and socio-demographic characteristics that are associated 
with virological failure (using an unsuppressed viral load as proxy) after 6 months on 
ART in those who initiated treatment as adolescents.  
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CHAPTER 2: MATERIALS AND METHODS 
This chapter gives a description of the materials and methodology used in conducting the 
study. It starts with an outline of the study design followed by a description of the study 
setting, population and selection criteria for the participating individuals. The data sources 
together with the datasets used to investigate the factors associated with virological failure 
are presented. This is followed by a description of the data management for the study which 
includes data measurement, definitions of the study variables and methods used to process 
and analyse the data. The chapter closes with a presentation of the ethical considerations for 
the study. 
2.1 Study Design 
The study is an analysis of data that were collected from a cohort of adolescents on ART at 
the AC as part of their routine surveillance and clinical care in the Hlabisa sub-district of 
KwaZulu-Natal.  
2.2 Study Setting 
2.2.1 Study Site 
The AC, established in 1997 and funded by the Wellcome Trust, is a population-based 
research centre at the University of KwaZulu-Natal. It conducts policy relevant health and 
population research in partnership with the local community and the local departments of 
health and education. It collects data twice a year from 85 000 individuals in the DSA which 
is 438 square kilometres [49] within the Hlabisa sub-district.  
The Hlabisa HIV Treatment and Care Programme is a decentralised programme which 
operates from 17 nurse-led primary health-care (PHC) clinics in the rural Hlabisa sub-district. 
Six of these PHC clinics and 40% of the programme individuals fall within the DSA. By 
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February 2012, 20 442 individuals had been initiated on ART in the programme, 66% 
(13492) of whom were females. 
The programme follows South African guidelines for the management of those infected by 
HIV. Until August 2011 eligibility for ART in adolescents were a CD4 count ≤ 200 cells/µl 
irrespective of clinical stage and a CD4 count ≤ 350 cells/µl in pregnant women and those 
with TB [15]. Those with WHO stage IV and those with multiple drug resistant/ extremely 
drug resistant (MDR/XDR) TB irrespective of their CD4 cell count were also eligible for 
ART [15]. The South African guidelines were revised in August  2011 in line with the WHO 
guidelines for eligibility [50]. The first line regimen for ART in adolescents in those > 15 
years old is Tenofovir (TDF) + (Lamivudine (3TC) or Emtricitabine (FTC)) + (EFV or NVP) 
[15] and those ≤ 15 years old use Abacavir (ABC) instead of TDF due to renal and bone side 
effects. Protease inhibitors are reserved for second line regimens. Individuals on ART are 
monitored monthly with viral loads and CD4 counts being done at 6 and 12 months after 
ART initiation and then yearly thereafter unless clinically indicated. The programme initiated 
psychological services for HIV care and support  in 2008 for people living with HIV 
(PLWHIV) and their carers [51]. This included support for the formation of support groups 
and developing the skills of healthcare givers through ART clinical and counselling training 
[51]. 
The study site was chosen as it has databases that contain both the clinical and socio-
demographic characteristics of adolescents who initiated ART. 
2.2.2 Data Sources at the study site 
Data for the study were extracted from two databases. The first database, the Antiretroviral 
Treatment Evaluation and Monitoring Information System (ARTemis), was established in 
2007 and includes clinical information on all HIV infected individuals managed in the 
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Hlabisa treatment and care programme from 2004. It captures both clinical and laboratory 
data at initiation, monthly follow up attendance and laboratory monitoring results (CD4 and 
viral loads) of participants. This database was used to obtain clinical data for all the 
adolescents (543) who initiated ART in the treatment programme. 
The second database, the Africa Centre Demographic Information System (ACDIS), contains 
twice yearly surveillance data collected from the DSA since the year 2000. Data are collected 
based on interviews with key-household informants and annual household socio-economic 
surveys. This database was used to obtain the baseline socio-demographic data for the 
adolescents (153) residing within the DSA at ART initiation.  
Though age and gender are viewed as demographic characteristics, they are described in this 
study under clinical characteristics because they were obtained from the ARTemis database 
for clinical characteristics. 
2.3 Study Population 
The study population included all individuals who initiated ART as adolescents at the Hlabisa 
Treatment and Care Programme in KwaZulu-Natal from 1 June 2004 to 31 December 2010. 
During this period, 543 individuals initiated ART as adolescents. 
2.4 Study Sample 
The programme started providing ART in June 2004 and 31 December 2010 was selected as 
the end date for inclusion in the analysis to allow at least 6 months of follow-up of 
individuals after ART initiation. This also allowed time for a viral load test to be done after at 
least 6 months of ART as the database closure was 31 October 2011. 
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2.4.1 Clinical characteristics dataset 
To investigate the clinical characteristics, the following criteria were used: 
Exclusion Criteria: 
 Those with less than 6 months follow up from the date of ART initiation 
 Those who did not have at least one viral load test result after 6 months of ART 
Out of the 543 adolescents who initiated treatment in the programme; 23 (4.2%) died, 54 
(9.9%)  were lost to follow up and 7 (1.3%) transferred out of the programme before 
achieving 6 months follow up after ART initiation. Of the 459 who were still in the 
programme after 6 months from the date of initiation, 95 (20.7%) had no viral load test result. 
This resulted in a sample of 364 adolescents who had a viral load result after 6 months of 
treatment. 
2.4.2 Socio-demographic characteristics dataset 
To investigate the socio-demographic characteristics, the following criteria were used: 
Exclusion criteria 
 Those who did not reside in the DSA at the time of ART initiation 
 Those with less than 6 months of follow up from the date of ART initiation 
 Those who did not have at least one viral load test result after 6 months of treatment 
Of the 543 who initiated treatment, 390 (71.8%) did not reside in the DSA at ART initiation. 
Only 101 (66%) of the 153 residing in the DSA at initiation had at least 6 months follow up 
and had a viral load result.  
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2.5 Data Management 
2.5.1 Measurement 
A multiple clerk and single entry system were used in both databases. For the ACDIS 
database, data were entered by clerks after questionnaires were barcode verified during the 
surveillance. Data entry for each individual was done twice yearly according to the 
surveillance schedule. 
Data for the ARTemis were collected as part of the routine monitoring of individuals who 
attend the Hlabisa Treatment and Care programme by health care workers. Data were entered 
by clerks into the database after the initiation visit. Thereafter laboratory results for 
monitoring were imported into the ARTemis directly from the relevant reference laboratories 
databases. Monthly clinic attendance as recorded by the healthcare givers was also entered 
into the database. Missing information including laboratory results were followed up at the 17 
clinics by the student and data missing from the database that were available in the clinic files 
were recorded on paper forms and subsequently entered into the database. 
The data was extracted by the senior database scientist from both databases using SQL Server 
2005. The datasets included the linked ACDIS and ARTemis data for those who resided in 
the DSA at initiation. 
2.5.2 Study Variables 
2.5.2a Outcome Variable 
The outcome was analysed as a dichotomous variable. It was defined as suppressed if the 
viral load was ≤ 70 copies/ml or unsuppressed if the viral load was >70 copies/ml.  
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2.5.2b Exposure Variables 
Clinical Variables 
 Age was defined and calculated as the time between the date of birth and date of ART 
initiation. To allow for comparisons of the characteristics of adolescents at the 
different levels of development, age was also analysed as a categorical variable. It 
was categorized as early (<15 years old) and late (≥15 years old) adolescent stages.  
 Gender was defined as the sex of the adolescent either male or female. 
 Age and gender are described as clinical variables as they were obtained from the 
ARTemis database for clinical characteristics 
 Clinical WHO stage was dichotomised, Stage 1 and 2 were combined as were stage 3 
and 4. It was the clinical stage recorded closest to the date of ART initiation. 
 Sex adjusted weight-for-age z-score (WAZ) were used to analyse weight at initiation 
as the weight varies with age, gender and stages of development. The use of body 
mass indices was precluded by the large number of missing data in the height 
variable. WAZ scores were calculated from the baseline weight and age observations 
using Microsoft Access 2007, the 1978 CDC/WHO growth reference curves and Epi 
Info Nutrition version 3.5.1 software. WAZ charts have an age range of 0 to 18 years 
therefore computation for those who were more than 18 years old at initiation was 
done using the age reference point of 18 years.  
It was categorised by whether the adolescent was malnourished (WAZ score ≤ 2) or 
not (WAZ score >2) [52] 
 The clinics of initiation were categorised by whether they were in the DSA or not.  
 Exposure to Tuberculosis (TB) was analysed as two variables and these were both 
dichotomised (Yes/No). The first variable was whether the adolescent had TB before 
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ART initiation and the second was whether the adolescent was on TB treatment at 
initiation of ART. 
 Year of initiation variable was analysed as a categorical variable with the initial years 
of ART roll-out 2004-2006 combined as there were low number of adolescents 
initiated during this early period of the ART roll-out. 
 Baseline CD4 cell counts were taken before initiation and were analysed as both a 
continuous and categorical variable. Categories were ≤100 cells/µl, 101-200 cells/µl 
and >200 cells/µl. The CD4 cell counts recorded closest to the ART initiation date 
were used as the baseline counts. 
 All other baseline laboratory test results (Haemoglobin, Creatinine, Albumin, Alanine 
transaminase and Platelets) were dichotomised depending on the normal ranges of the 
test. All tests were done before initiation and the test results closest to the ART 
initiation date were used as the baseline results.  
 Drug regimens at initiation were categorised according to the drug included in the 
first line regime (EFV, NVP or Lopinavir (LPVr)). 
 Time to viral load test was used to adjust for the different times at which the 
individuals had their first viral load tests done after 6 months of treatment. The 
different times for viral load testing were mostly due to health care provider reasons. 
The variable was categorised as 6-12 months, 13-18 months, 19-24 months, 25-30 
months and > 30 months. 
Socio-demographic variables 
 Education level was defined as the school grade the adolescent was in at initiation of 
treatment. This was categorised as primary or secondary/tertiary. 
 School attendance was dichotomised according to whether the adolescent was 
currently attending school or not at ART initiation. 
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 “Mother and father dead at initiation” were analysed as categorical variables 
according to whether the mother/father was alive, dead or it was unknown at 
initiation. 
 Distance from nearest clinic was analysed as a continuous variable in kilometres. It 
was calculated to be the distance from the homestead at ART initiation to the nearest 
clinic.  
2.5.3 Data Quality Control 
To identify inconsistencies in the data, consistency checks were done e.g. whether dates of 
births were less than date of ART initiation. Range checks using histograms and box plots for 
continuous variables were done to check for outliers. Duplicate checks were performed and if 
found these were removed. 
2.5.4 Data Processing Methods and Analysis 
STATA version 11 (STATA Corporation, College Station, TX) software package was used 
for all statistical analysis. A significance level of 5% was used except for the univariable 
analysis where a significance level of 20% to ascertain inclusion into the multivariable model 
was used. 
To achieve the first objective of the study, frequencies were used to describe the categorical 
variables such as gender and TB at initiation. Continuous variables were tested for the 
assumption of normality using histograms, normal quantile plots and standardised normal 
probability plots (Appendix 1). Medians and interquartile ranges were used to summarize all 
the continuous variables as none of them were normally distributed. Graphs were also used to 
describe the study population. Kaplan Meier estimates for time from ART initiation to death 
and lost to follow up (LFTU) were used to describe the attrition rates of the group. 
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The prevalence of an unsuppressed viral load (>70 copies/ml) was calculated as a proportion 
of those with a viral load result after at least 6 months on treatment. 
To investigate the association between an unsuppressed viral load and the categorical clinical 
and socio-demographic characteristics, Chi-square test of proportions were used. For testing 
the association between the continuous variables and an unsuppressed viral load, the 
Wilcoxon rank-sum test was used.  
The multivariable method of analysis used to investigate the characteristics associated with 
an unsuppressed viral load was logistic regression because the outcome was dichotomous. 
Due to low numbers in the socio-demographic characteristics and the large proportions of 
missing data, they were only analysed using Chi-square test of proportions and Wilcoxon 
rank-sum test. To analyse the clinical characteristics, univariable logistic regression models 
were used to ascertain if the factors were statistically significant. These were added to the 
multivariable model starting with the one with the smallest p-value. The Mantel-Haenzsel test 
and interaction terms between variables were used to explore and to investigate effect 
modification. During the multivariable model building, a likelihood ratio test was used to 
assess improvement of the model after each addition of a new variable. The final 
multivariable model obtained was assessed using the Pearson chi-square goodness-of-fit test.  
Missing data were followed up at the clinics in the treatment programme by the student and 
those found were added to the analysis (Appendix 2). Analyses using Chi-square and 
Wilcoxon rank-sum tests were done to investigate characteristics associated with the 
individuals who were on ART for at least 6 months and did not have a viral load result 
compared to those on ART for at least 6 months and had viral load results (Appendix 3). 
Missing data in the exposure variables were included as a category in the logistic regression 
analysis to find their trends and associations with an unsuppressed viral load.  
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2.6 Ethical Considerations 
This study was performed anonymously using ARTemis and ACDIS identification numbers. 
Any potential individual identifiers were removed from the dataset by the senior database 
scientist. Storage of the datasets was in a password restricted laptop. Guardian consent and 
assent from individuals less than 18 years of age and individual consent from those above 18 
years of age was obtained for the use of their information in both the treatment programme 
and the surveillance. Data use agreements were obtained by the student from AC (Appendix 
6). Ethical approval to conduct the study was obtained from the University of Witwatersrand 
Ethics Committee on Human Research on 28/10/2011, clearance certificate number M111131 
(Appendix 4). A change of title for the research from “Predictors of virological failure in 
adolescents at a rural HIV programme in Kwazulu-Natal” to “Factors associated with 
virological failure in adolescents in a rural HIV programme in Kwazulu-Natal” was granted 
by the Faculty of Health (Appendix 7). The study was also conducted adhering to the ethics 
requirements of the University of KwaZulu-Natal. The AC had permission from the 
Biomedical Ethics Committee of the University of KwaZulu-Natal for linkage of data from 
ARTemis to the data from ACDIS, current ethics number for the linkage is E134/06 
(renewable annually). All results were given to the Africa Centre for Health and Population 
Studies as per the Africa Centre policy to be used in the improvement of the management of 
HIV positive adolescents especially in KwaZulu-Natal.  
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CHAPTER 3: RESULTS 
This chapter presents the results of the study with the main aim of achieving the objectives of 
the research. A description of the baseline cohort clinical characteristics of the study sample 
opens the chapter followed by a description of the socio-demographic characteristics of those 
who initiated ART whilst residing in the DSA. The prevalence for the period 2004 to 2011 of 
an unsuppressed viral load after 6 months on ART is reported. The associations between an 
unsuppressed viral load and baseline clinical and socio-demographic characteristics are 
explored. The chapter closes with an identification and report of the characteristics that were 
associated with an unsuppressed viral load after the adjusted multivariable analysis.  
3.1 Cohort characteristics  
A total of 543 individuals were initiated on ART as adolescents at the Hlabisa Treatment and 
Care programme between June 2004 and December 2010 and these were followed up to 31 
October 2011. Figure 1 shows the flow chart of adolescents who were included in the final 
analysis for investigating clinical characteristics that were associated with an unsuppressed 
viral load.  Figure 2 shows the flow chart of adolescents who were included in the final 
analysis for investigating the association between household socio-demographic 
characteristics and an unsuppressed viral load. 28.2% (153) of the adolescents initiated 
treatment whilst residing in the DSA. 
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Figure 1: Flow chart of adolescents included in the study to investigate the clinical 
factors that were associated with an unsuppressed viral load  
 
 
 
 
543 initiated ART as adolescents at the Hlabisa HIV Treatment and 
Care Programme between 1 June 2004 and 31 December 2010 
23 excluded: Died before 6 
months of ART  
54 excluded: Lost to follow up 
before 6 months of ART 
7 excluded: Transferred out 
before 6 months of ART 
459 alive and on ART for at least 6 
months  
95 excluded: Did not have a viral 
load result after 6 months on ART 
364 had viral load results after 6 
months of ART and were included 
in the analysis 
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Figure 2: Flow chart of adolescents included in the study to investigate the socio-
demographic factors associated with an unsuppressed viral load 
 
 
 
543 initiated ART as adolescents at the Hlabisa HIV Treatment and 
Care Programme between 1 June 2004 and 31 December 2010 
7excluded: Died before 6 months 
of ART  
15 excluded: Lost to follow up 
before 6 months of ART 
131 alive and on ART for at least 6 
months  
30 excluded: Did not have a viral 
load result after 6 months on ART 
101 had viral load results after 6 
months of ART and were included 
in the analysis 
153 initiated ART whilst 
residing in the DSA 
390 excluded: did not initiate 
ART whilst residing in the DSA 
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3.1.1 Baseline Clinical Characteristics 
Figure 3 shows the yearly number of adolescents initiating ART at the Hlabisa Treatment and 
Care Programme. There was a steady increase in the number of adolescents who initiated 
ART over the period 2004-2009 with a total of 53 in 2004-2006 and 129 in 2009. From 2009 
to 2010 there was a steep increase in ART initiation. 
 
Figure 3: Frequency of ART initiation by year  
Table 2 below summarises the baseline cohort clinical characteristics of the study population 
and this includes the proportion of missing data for each variable. The median age for ART 
initiation was 15 years (IQR 12-18) and 271 (49.9%) initiated whilst they were in early 
adolescence (aged 10-14 years). The adolescents in this study had a bimodal distribution of 
age at initiation with a peak between 10-12 years and a steep increase after 17 years (Figure 
4). More females (368, 67.8%) than males initiated on ART in this cohort. Of the females 16-
19 years old (222), 61 (27.5%) initiated ART whilst pregnant. Out of the 543 who initiated 
ART, 129 (23.8%) were malnourished with a WAZ score of -2 or less at initiation. The 
majority of the adolescents initiated treatment at a relatively advanced disease stage (WHO 
stage 3/4) though 147 (27.1%) of them had missing data. The median CD4 cell count at 
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initiation was 152cells/µl (IQR 79-251) and 163 (30%) initiated with a CD4 cell count of ≤ 
100. Most of the adolescents (408) initiated ART on EFV containing regimes. At initiation, 
103 (19%) were on TB treatment and 151 (27.8%) had been diagnosed with TB before 
treatment initiation. The majority of those who initiated had normal blood laboratory results 
of Heamoglobin, Platelets, ALT, Creatinine and Albumin. 
Table 2: Baseline clinical characteristics of adolescents initiating on ART 
Characteristic (n=543)    n                % 
 
Age  (years)  
Median  (IQR) 
10-14 (early adolescence)      
15-19 (late adolescence) 
 
 
 
  15 (12-18) 
271               49.9 
272               50.1 
Gender    
Female 
Male 
 
 
368               67.8 
175               32.2 
WHO Stage 
1/2 
3/4 
Data missing 
 
WAZ score  
Median (IQR) 
>-2  
≤-2 
Data missing 
 
 
130               23.9  
266               49.0 
147               27.1 
 
 
-1.2 (-2.0 to -0.1) 
368               67.8 
129               23.8 
  46                 8.4 
Initiation Clinic  
Clinics in the DSA 
Clinics not in the DSA 
Data missing 
 
 
213               39.2 
316               58.2         
  14                 2.6  
Prior TB  
No 
Yes 
 
 
392               72.2 
151               27.8 
On TB treatment   
No 
Yes 
Data missing 
 
 
409               75.3 
103               19.0  
  31                 5.7 
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CD4 cell count                  
Median  (IQR) 
≤100 cells/µl 
101-200 cells/µl  
>200 cells/µl 
Data missing 
 
 
152 (79-251) 
163               30.0 
187               34.4 
178               32.8 
  15                 2.8         
Haemoglobin   
>7g/dl 
≤7g/dl 
Data missing 
 
 
419                77.2 
  43                  7.9 
  81                14.9 
Creatinine  
≤120 µmol/L 
>120 µmol/L 
Data missing 
 
 
454               83.6 
    5                 0.9   
  84               15.5 
ALT             
≤60 IU/L 
>60 IU/L 
Data missing 
 
 
438               80.6 
  21                 3.9 
  84               15.5 
Platelets   
>150 000 per µl 
≤150 000 per µl 
Data missing 
 
 
415               76.4 
  33                 6.1 
  95               17.5  
Albumin    
>25 g/L 
≤25 g/L 
Data missing 
 
 
337               62.1 
108               19.9 
  98               18.0 
Drug regime  
EFV containing 
NVP containing 
LPVr containing 
 
 
408               75.1 
132               24.3 
    3                 0.6 
 
Figure 4 shows the distribution by age and gender of the adolescents initiating ART. The 
distribution of ART initiation by gender was equal in early adolescence but in late 
adolescence the majority were females (236, 86.8%). There was a sharp increase in the 
number of females who initiated ART after 15 years of age whereas there was a decrease in 
males initiating ART after this age. 
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Figure 4: Frequency of ART initiation by Age and Gender 
Figure 5 below shows the median WAZ score at initiation by gender and age. According to 
the WHO, WAZ scores of ≤ -2 are indicative of malnourishment [52]. The lower the WAZ 
score the more malnourished the individual. The overall median WAZ scores at initiation 
were generally >-2 reaching > 0 for those 19 years old. After the age of 14, the females had 
better nutritional status (WAZ scores >-2) compared to the males (WAZ scores ≤-2). This 
shows that those who initiated ART in late adolescence had better nutritional status than 
those in early adolescence (p<0.001). The females had better nutritional status than males at 
ART initiation (p<0.001).     
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Figure 5: Median WAZ score at initiation by Age and Gender 
3.1.2 Baseline socio-demographic characteristics 
Those who initiated ART whilst residing in the DSA constituted 28.2% (153) of the cohort. 
Table 3 below summarises the socio-demographic characteristics of adolescents who initiated 
ART whilst residing in the DSA. Of the 153 who initiated whilst residing in the DSA, 61 
(39.9%) had primary education as the highest education level at initiation though 50 (32.6%) 
had missing data. A total of 70 (45.8%) were attending school at initiation. Mothers were 
alive at initiation for 78 (51%) of the adolescents. It was not known whether the mother and 
father were dead or alive for 48 (31.3%) and 106 (69.2%) respectively of those who initiated 
whilst residing in the DSA. The median distance between the homestead at initiation and the 
nearest clinic was 2.2km (IQR 1.28-3.46). 
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Table 3: Socio-demographic characteristics of adolescents initiating on ART  
Characteristic (n=153)    n              % 
 
Highest Education level       
Primary 
Secondary/Tertiary 
Data missing 
 
 
  
 61                39.9 
 42                27.5 
 50                32.6 
Attending school   
No      
Yes 
Data missing 
 
 
 34                22.2             
 70                45.8 
 49                32.0 
Mother dead  
No 
Yes 
Unknown 
 
 
 78                51.0         
 27                17.7      
 48                31.3 
Father dead  
No 
Yes 
Unknown 
 
 
  29               19.0        
  18               11.8       
106               69.2 
Distance from Clinic (km)        
Median (IQR) 
Data missing  
 
2.20 (1.28-3.46) 
 37               24.2 
 
3.1.3 Cohort Clinical Outcomes 
The overall attrition rate for the study period was 38.3% (95% CI 34.2-42.4). After 6 months 
of follow up, the attrition rate was 15.5% (95% CI 12.3-19.2); 23 (4.2%) had died, 54 (9.9%) 
were LTFU and 7 (1.3%) had transferred out to other programmes. 
The adolescents contributed a total of 1234.39 person years, with a median follow up time of 
2 years (IQR 1.2-3.2). The median CD4 cell count increase from ART initiation to the first 
CD4 cell count test after 6 months was 211 cells/µl (IQR 71-359). LTFU was defined as the 
adolescent having no contact with the ART programme for more than 6 months before 31 
October 2011 and was not known to have died or transferred out [33]. The overall incidence 
of LTFU was 98.8 per 1000 person years (95% CI 82.8-118). The unadjusted LTFU rates 
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were significantly different between females (122.0 per 1000 person years (95% CI 99.7- 
149.4)) and males (60.3 per 1000 person years (95% CI 41.7- 87.4)). The unadjusted LTFU 
rates were also significantly different between those initiating in early and late adolescence, 
37.2 per 1000 person years (95% CI 25.7- 53.8) and 195.4 per 1000 person years (95% CI 
159.6- 239.2) respectively. After adjusting for the adolescent developmental stage and 
gender, LTFU was highest in the females who initiated in late adolescence (p<0.001) 
(Appendix 5). Of those who initiated whilst pregnant (61), 39.3% (24) were LTFU. Those 
initiating in late adolescence contributed 83.5% of the LTFU before 6 months of ART. 
The overall mortality rate was 36.5 per 1000 person years (95% CI 27.2 - 48.8). Mortality 
was not significantly different by gender and age category (Appendix 5).  Assuming that 50% 
of those LTFU died, the mortality would be 85.9 per 1000 person years (95% CI 71.0-103.9). 
Of the 43 known to have died during the study period, 22 (51%) did so during the first 6 
months of ART. Of the adolescents who died before 6 months, 12 (52.2%) initiated whilst 
severely immunocompromised (CD4 cell count ≤ 100 cells/µl).  
3.2 Prevalence of an unsuppressed viral load 
Of the 543 adolescents in the cohort, 459 were at least 6 months on ART and 364 (79.3%) of 
these had a viral load test result. The median time for the first viral load to be taken after 
initiation was 11.25 months (IQR 7.78-16.20). At the end of the study period, out of the 95 
without a viral load; 43 (45.2%) were alive, 28 (29.5%) were LTFU, 9 (9.5%) died and 15 
(15.8%) transferred out of the programme. There were significant differences by gender, 
adolescent developmental stage at initiation, drug regime at initiation and ART initiation by 
year between adolescents with no viral load results compared to those with a result 
(Appendix 3).  
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Of the 364 adolescents with a viral load result, 119 were not suppressed resulting in an 
overall prevalence of an unsuppressed viral load of 32.7% (95% CI 27.1- 39.1). Male 
adolescents had a higher prevalence of an unsuppressed viral load than female adolescents, 
37.2% (95% CI 28.0- 48.6) and 29.7% (95% CI 22.9- 37.8) respectively though this is not 
statistically significant.   
Figure 6 shows the prevalence of an unsuppressed viral load by the age of ART initiation. 
Those who initiated whilst aged 12 had the highest prevalence of an unsuppressed viral load 
(45.7%). Those aged 15 and 19 had the lowest prevalences 23.5% and 23.3% respectively. 
 
Figure 6: Age Specific Prevalence of an unsuppressed viral load 
3.3 Characteristics associated with an unsuppressed viral load 
Table 4 summarises the clinical and socio-demographic characteristics associated with an 
unsuppressed viral load. Of those who initiated with WHO stage 1/2, 25.3% (24) had a 
suppressed viral load. The association between baseline WHO stage and an unsuppressed 
viral load was significant (p=0.05). Having prior TB at ART initiation was significantly 
associated with an unsuppressed viral load (p=0.027). Of those who had TB before ART 
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initiation, 41.1% (44) had an unsuppressed viral load compared to 29.2% (75) of those who 
had not had TB. The year of ART initiation and time taken for a viral load to be taken were 
associated with an unsuppressed viral load. No socio-demographic characteristic was 
associated with an unsuppressed viral load. 
Table 4: Associations between baseline clinical and socio-demographic characteristics 
and an unsuppressed viral load (n=364) 
Characteristic n (%)                   Viral Load    p value 
 Suppressed            Unsuppressed      
     
Age  (n=364) 
Median (IQR) 
10-14 years 
15-19 years 
 
Gender  (n=364) 
Female 
Male 
 
WAZ score  (n=342) 
Median (IQR)  
>-2 
≤-2 
 
WHO Stage  (n=285) 
Stage 1/2 
Stage 3/4 
 
Initiation clinic  (n=353) 
In DSA 
Not in DSA 
 
Prior TB   (n=364)  
No 
Yes 
 
On TB treatment  (n=353)  
No 
Yes 
 
CD4 cell count  (n=352) 
Median (IQR) 
≤100 cells/µl 
101-200 cells/µl 
>200 cells/µl 
 
 
  13 (11-18) 
144           (65.2) 
101           (70.6) 
 
 
154           (70.3) 
  91           (62.8) 
  
 
-1.3 (-2.0 to -0.2 ) 
172           (69.1) 
  58           (68.2)           
 
 
  71           (74.7)        
120           (63.2)      
   
 
  91           (62.8)    
147           (70.7) 
 
 
182           (70.8)        
  63           (58.9) 
 
 
192           (67.6)        
  44           (63.8)        
 
 
152 (78-246) 
  74           (67.3) 
  78           (66.7) 
  84           (67.2)  
 
 
  13 (11-17) 
  77             (34.8) 
  42             (29.4) 
 
 
  65             (29.7) 
  54             (37.2) 
 
 
-1.4 (-2.2 to -0.3) 
  77            (30.7) 
35            (37.6) 
 
 
  24            (25.3) 
  70            (36.8) 
 
 
  54            (37.2)        
  61            (29.3) 
 
 
  75            (29.2) 
  44            (41.1) 
 
 
  92            (32.4)       
  25            (36.2)       
 
 
164 (68-302) 
  36             (32.7) 
  39             (33.3) 
  41             (32.8)    
 
              
0.503 
            
0.277 
  
  
            
0.132 
      
       
0.407 
              
0.239                
 
 
 
0.050 
   
              
              
0.119  
            
   
         
0.027 
 
   
         
0.544            
 
 
0.838 
 
             
0.944 
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Year of initiation  (n=364)  
2004-2006 
2007 
2008 
2009 
2010 
 
Haemoglobin  (n=316) 
>7g/dl 
≤7g/dl 
 
Platelets  (n=305) 
>150 000 per µl 
≤150 000 per µl 
 
ALT  (n=323) 
≤60 IU/L 
>60 IU/L 
 
Albumin  (n=316)   
>25 g/L 
≤25 g/L 
 
Drug Regime  (n=361)    
EFV containing 
NVP containing  
LPVr containing 
 
Time to viral load test (n=364) 
6-12 months 
13-18 months 
19-24 months 
25-30 months 
> 30 months 
 
Highest Education level  (n=73)  
Primary School 
Secondary School 
 
Attending school  (n=72) 
No 
Yes 
 
Mother dead  (n=101) 
No 
Yes 
Unknown 
 
 
 
 
  27           (62.8) 
  37           (69.8) 
  42           (59.2) 
  49           (53.9) 
  90           (84.9) 
 
 
198           (67.4)         
  14           (63.6)      
 
 
190           (67.4)  
  15           (65.2)       
 
 
210           (68.2)                                                       
    8           (53.3) 
 
 
167           (66.8)                                 
  43           (65.2)   
 
 
196           (67.1) 
  46           (66.7)  
    3           (100) 
 
   
147           (72.8) 
  60           (64.5)  
  23           (57.5)    
  13           (65.0) 
    2           (22.2) 
 
 
  33           (64.7)        
  14           (63.6)        
 
 
  12           (66.7)       
  34           (63.0)                   
 
 
  30           (62.5)      
  14           (63.6)      
  19           (61.3) 
 
 
   
 
  16             (37.2) 
  16             (30.2) 
  29             (40.8) 
  42             (46.1) 
  16             (15.1) 
 
 
  96            (32.6) 
    8            (36.4)       
 
 
  92             (32.6) 
    8             (34.8) 
 
 
98 (31.8)        
    7             (46.7)        
 
 
83 (33.2)       
  23             (34.8)  
 
 
  96             (32.9) 
  23             (33.3) 
                       (0) 
 
   
  55              (27.2) 
  33              (35.5)    
  17              (42.5) 
    7              (25.0)     
    7              (77.8) 
  
 
  18             (35.3)       
    8             (36.4)       
 
 
    6             (33.3)        
20          (37.0)        
 
 
  18             (37.5)        
    8             (36.4)     
  12             (39.7) 
 
 
   
     
  
 
 
          
<0.001 
                            
 
 
0.721   
 
 
              
0.832 
     
   
   
0.231   
 
 
           
0.801 
 
 
 
 
0.478 
 
 
 
 
 
 
0.010 
 
 
 
0.930 
 
 
0.778 
 
 
 
0.985 
 
 
 
38 
 
Father dead  (n=101) 
No 
Yes 
Unknown 
 
Distance from Clinic  (n=80) 
Median (IQR) 
 
  15            (88.3) 
    4            (40.0) 
  44            (60.3)   
 
 
2.35  (1.26-3.16)   
 
   3             (11.7)   
   6             (60.0) 
 29             (39.7) 
 
 
2.20 (1.47-3.52)    
 
 
 
0.052 
 
 
0.467 
  
 
3.4 Clinical factors associated with an unsuppressed viral load after logistic regression 
Both the univariable (unadjusted) and multivariable (adjusted) logistic regression models 
used to investigate the associations of characteristics with an unsuppressed viral load are 
included in Table 3.5. The odds ratio (OR) for each variable is shown together with the 95% 
CI. The final multivariable model had a Pearson chi-square goodness-of-fit of p=0.3396 
indicating that the model has a good fit for the data used in this study.  
Having had TB before initiation was significantly associated with an unsuppressed viral load 
in the unadjusted analysis. The odds of having an unsuppressed viral load were 69% more in 
those who had TB before initiation than those who did not (95% CI 1.06-2.71). The 
univariable model for the year of initiation was significant (p<0001). Also in the unadjusted 
analysis, adolescents who initiated in 2010 were 70% less likely to fail than those who 
initiated in 2004-2006 (95% CI 0.13-0.68). Those who had a baseline WHO Stage 3/4 were 
73% more likely to have an unsuppressed viral load than those with a baseline WHO Stage 
1/2 (95% CI 1.00-2.99) in the unadjusted model. In the unadjusted model, those who had 
greater than 30 months before the first viral load was done were more than 9 times more 
likely to have an unsuppressed viral load than those who had a viral load between 6 and 12 
months though the CI is very wide (95% CI 1.89-46.40). 
The variables gender, WHO stage and clinic of initiation were significant at the 20% level 
and were included in the multivariable model. The variables age (as a continuous variable), 
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categorised CD4 at initiation and the initial treatment regime were included in the final 
multivariable model as they have been previously shown to be associated with virological 
failure in children and adults. There was no significant univariable association of an 
unsuppressed viral load with categorised age at initiation, having been on TB treatment at 
initiation, baseline Haemoglobin, Platelets, ALT and Albumin. 
Adjusting for the other variables, in the multivariable model, adolescents who initiated ART 
in 2010 had 68% less odds of having an unsuppressed viral load as compared with those 
initiating in 2004-2006 (95% CI 0.13-0.82). Adolescents whose viral load test was done after 
30 months of ART were more than 7 times more likely to have an unsuppressed viral load 
compared to those done after 6-12 months although the CI is wide and therefore imprecise 
(95% CI 1.50-41.04).   
Though not statistically significant, the trends in the adjusted model of the other 
characteristics are important to report. With each yearly increase of age at ART initiation, 
there was a 2% increase of having an unsuppressed viral load. The males were 58% more 
likely to have an unsuppressed viral load than the females. Initiating whilst in WHO stage 3/4 
was associated with 11% odds of an unsuppressed viral load compared to those initiating in 
WHO stage 1/2. Initiating ART outside the DSA had a protective effect on an unsuppressed 
viral load. The individuals who had TB before ART were 54% more likely to have an 
unsuppressed viral load than those who did not have prior TB. No trend was found in the 
CD4 cell count variable. Those who initiated ART on NVP were 14% more likely to have an 
unsuppressed viral load than those who initiated on EFV. All missing data were not 
associated with an unsuppressed viral load.  
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Table 5: Logistic regression: Factors associated with an unsuppressed viral load (n=364) 
Characteristic            OR (95% CI)        Adjusted OR (95%CI)                                                                                                                   
 
Age (years)**             
Age group  
10-14 years  
15-19 years  
 
  
         0.97 (0.91-1.04)   
            
               1 
          0.78 (0.49-1.22)  
 
1.02 (0.93-1.13)  
 
Gender  
Female  
Male  
 
                
               1 
          1.41 (0.90-2.19)* 
 
                1          
1.42 (0.82-2.46)   
WAZ score  
>-2       
≤-2  
Missing data 
 
       
               1                                                       
          1.35 (0.82-2.22)    
          1.04 (0.41-2.66)        
 
WHO Stage 
Stage 1/2 
Stage 3/4 
Missing data 
 
                
               1 
          1.73 (1.00-2.99) * 
          1.37 (0.71-2.66)  
              
               1    
          1.11 (0.56-2.19)  
          1.25 (0.60-2.60)         
Initiation clinic 
In the DSA 
Not in the DSA 
Missing data 
 
 
               1 
          0.70 (0.45-1.10)* 
          0.96 (0.27-3.44) 
 
                1 
0.63 (0.39-1.04)  
0.65 (0.14-3.05)  
Prior TB  
No   
Yes 
 
 
               1 
          1.69 (1.06-2.71)* 
 
                1                       
1.46 (0.81-2.63)  
On TB treatment  
No 
Yes 
Missing data 
 
 
               1 
          1.19 (0.68-2.06)    
          0.46 (0.10-2.19)       
 
 
CD4 cell count**  
≤100 cells/µl 
101-200 cells/µl 
>200 cells/µl 
Missing data 
 
 
               1 
          1.03 (0.59-1.79)  
          1.00 (0.58-1.73)  
          0.69 (0.17-2.69)  
 
               1 
1.00 (0.54-1.83)  
1.00 (0.55-1.86)  
0.64 (0.13-3.11)  
Year  
2004-2006 
2007 
2008 
2009 
2010   
 
          
               1 
          0.73 (0.31-1.71)  
          1.17 (0.53-2.54)  
          1.44 (0.69-3.04)  
          0.30 (0.13-0.68)* 
 
                1          
0.57 (0.22-1.49)          
1.08 (0.45-2.61)       
1.44 (0.63-3.32)         
0.32 (0.13-0.82)§                      
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Haemoglobin    
>7g/dl 
≤7g/dl 
Missing data 
 
 
               1 
          1.18 (0.49-2.91)  
          0.94 (0.49-1.81)  
 
 
Platelets      
>150 000 per µl 
≤150 000 per µl 
Missing data 
 
 
               1       
          1.10 (0.45-2.69)  
          0.98 (0.54-1.79)  
 
 
ALT            
≤60 IU/L 
>60 IU/L 
Missing data 
 
   
               1 
          1.88 (0.66-5.32)  
          1.11 (0.56-2.21)   
 
 
Albumin     
>25 g/L 
≤25 g/L 
Missing data 
 
 
               1  
          1.08 (0.61-1.90)    
          0.75 (0.38-1.49)  
 
 
Drug Regime** 
EFV containing 
NVP containing 
 
     
              1 
         1.02 (0.58-1.78)  
 
1                   
1.17 (0.55-2.49)                                 
Time to viral load test 
6-12 months 
13-18 months 
19-24 months 
25-30 months 
> 30 months 
 
              1 
         1.47 (0.87-2.49)  
         1.98 (0.98-3.98)  
         1.44 (0.55-3.80)  
         9.35 (1.89-46.4)*      
0 
 
     1 
1.41 (0.79-2.50)  
1.60 (0.74-3.44)  
0.89 (0.31-2.54)  
7.84 (1.50-41.04)§   
* p <0.2 included in the multivariate logistic regression model 
**Variables included in the multivariable model as they were significantly associated with 
virological failure in the literature 
§ p <0.05 in the adjusted model 
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CHAPTER 4: DISCUSSION 
This chapter discusses the results that were found in this study. The study’s main objective 
was to describe the characteristics of adolescents who initiated ART and to identify 
characteristics that are associated with ART failure in this population. It opens with the 
discussion of the results obtained in respect of each objective which is followed by the 
discussion of possible limitations of the study. The chapter closes with a discussion of the 
generalizability and external validity of the research results. 
 4.1 Cohort Characteristics 
4.1.1 Clinical and Socio-demographic Characteristics 
In keeping with goal 6 of the South Africa National Strategic Plan for HIV/AIDS and STI 
2007-2011 of scaling up ART coverage [53], the  numbers of adolescents who initiated ART 
increased nearly fourfold from the early years of ART roll out (2004-2006) to 2010. The 
steep increase in ART initiation from 2009 is a reflection of the improved identification of 
HIV positive people through the provider initiated HIV testing in the programme [12]. The 
median age at initiation was 15 years, slightly younger than those in a study of 154 
adolescents with non-perinatally acquired HIV infection where the median age was 16.4 
years [22] but older than another study where 72.3% of the adolescents had acquired HIV 
perinatally, where the median age at initiation was 11.5 years [30]. The median age for sexual 
debut obtained from the 2006 AC sexual behaviour and HIV surveillance for adolescents 15-
19 years in the DSA was 16 years and 17 years for males and females respectively and this 
research also reported strong evidence that death of a mother for females was associated with 
increased vulnerability to earlier sexual debut and HIV infection [54]. This may indicate that 
those who initiated ART in late adolescence may have acquired HIV sexually. With the 
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reports of the clinical latency of HIV infection ranging from 4 years in rapid progressors [55] 
to 15 years in long term non-progressors [56, 57], differentiation of whether those initiating 
ART in late adolescence had perinatally or sexually acquired HIV infection is difficult. The 
females in this cohort may have been infected sexually and progressed rapidly with a short 
clinical latency period. They may also have been infected through breastfeeding and were 
long term non-progressors with a long clinical latency of HIV. Further analysis to distinguish 
the two is needed as they have different characteristics [58] which may result in different 
responses to ART and therefore virological failure. 
This study reports that two thirds of those initiating ART as adolescents at the Hlabisa HIV 
Treatment and Care Programme were females, this is similar to the gender distribution in 
other ART programmes [12, 22, 30] where more females than males are registered. In early 
adolescence the proportion of males and females who initiated ART are similar. This differs 
from late adolescence where more females than males initiate ART- only 13.2% of those who 
initiated in late adolescence were males. This could be a reflection of the Hlabisa HIV 
Treatment and Care Programmes PMTCT initiatives where testing for HIV is high, 95.6% of 
women attending the antenatal clinic are tested and are referred for ART if eligible [59].  
The median WAZ score distribution by age indicates that those who initiated in late 
adolescence had better nutritional status. This could further support the argument that those 
who initiated in late adolescence were sexually infected rapid progressors rather than 
perinatally infected long term non-progressors who often present with poor nutritional status 
from years of chronic illnesses. After 13 years of age the females had better nutrition than 
their male counterparts at ART initiation. Prevalence of obesity is higher amongst females 
than males in the DSA [60, 61] and this explains why females have better nutrition than boys 
at ART initiation. Nutritional status has been associated with clinical outcomes on ART [62] 
though it has not been found to be associated with virological failure [38]. 
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About 40% of the adolescents who initiated ART did so whilst residing in the DSA, this is 
similar to results found on the overall analysis of the Hlabisa Treatment and Care programme 
[12]. The ART programme is decentralised and individuals collect their drugs at the clinic 
nearest to their homesteads.  The median distance (2.2 km) from the homestead to the nearest 
clinic is relatively short compared to distances from clinics in the earlier years [63] and this 
may result in good pick up rates of drugs and therefore good ART adherence and virological 
outcomes. The number of adolescents without knowledge of whether the father is dead or 
alive is very high (69.2%) and this may be a reflection on the low marriage rates amongst 
women African women in KwaZulu-Natal [64]. Absence of a father has been shown to 
influence adolescent sexual behaviour [54] and their absence may also impact on adherence 
to ART and hence virological outcomes. 
4.1.2 Clinical Outcomes 
The mortality rate of 36.5 per 1000 person years for adolescents initiating ART at the Hlabisa 
HIV Treatment and Care programme is similar to that at other ART programmes in southern 
Africa [22, 30]. As in other programmes mortality is high in the first months of ART 
initiation [30, 65] and this is probably caused by initiating ART whilst severely 
immunocompromised, emphasising the need to seek medical care and start ART early. 
Overall LTFU (98.8 per 1000 person years) is similar to that for 9-19 year olds at a Cape 
Town programme (10.0 per 100 person years). The unadjusted LTFU rates between June 
2004 and October 2011 were significantly different between the adolescent developmental 
stages with those initiating in late adolescents having a higher LTFU rate. This is similar to 
results from a study in Malawi which concluded that LTFU was higher in those 15-24 years 
old than those 6-14 years [66]. During late adolescence, an individual becomes more 
independent and distances themselves from guardian supervision and there is greater chance 
of becoming lost to follow up [67]. Social groups and the need for acceptance by peers 
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become important during this phase and the stigma of being HIV positive may result in the 
high rates of LTFU [67]. The unadjusted LTFU rate by gender was significantly higher for 
females than males and this could be because of cultural and social reasons of gender roles, 
marriage and pregnancy. The rate of LTFU in those initiating whilst pregnant is high and this 
poses a public health concern as the HIV status of their infants needs to be determined so as 
to initiate them on ART if necessary. This highlights the need for intense adherence 
counselling and active follow up of adolescents on ART. The attrition rate for the adolescents 
after 6 months of ART was 15.5% and it is greater than that of children ≤ 15 years (6%) in 
the same programme [34]. This is mostly due to those in late adolescence who contributed 
83.5% of those LTFU before 6 months of ART. This high attrition rate may result in survival 
bias as those who died and were LTFU may have had poor virological response to ART.  
4.2 Prevalence of an unsuppressed viral load 
The proportion of an unsuppressed viral load in this study (32.7%) is lower than that reported 
for adolescents in other studies [22, 30, 39, 68]. Despite the lower threshold (≤ 70 copies/ml) 
used to determine viral suppression in this study compared to a threshold of ≤ 400 copies/ml 
in these other studies, adolescents in this cohort had a better virological outcome after 6 
months of ART. This result might indicate better adherence and lower rates of baseline ARV 
drug resistance compared to the adolescents in other studies. Though males had a higher 
prevalence of an unsuppressed viral load than females, it was not statistically significant.   
4.3 Factors associated with an unsuppressed viral load 
This study did not find any association between baseline age, gender, baseline weight, WHO 
stage, baseline CD4 cell count, baseline treatment regime and other baseline laboratory 
variables with an unsuppressed viral load. This is similar to previous studies done in 
adolescents which only showed that prior exposure to ART, T-cell immunological markers 
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and adherence to treatment to be associated with virological failure [37, 39, 40]. Studies done 
in children and adults showed that baseline age, gender, baseline CD4 cell count, baseline 
treatment regime were associated with virological failure. The small sample size in this study 
could be a limitation in finding significant clinical and socio-demographic characteristics that 
are associated with an unsuppressed viral load as were found in children and adults. The 
associations of a missing viral load, despite being eligible for testing, with gender, adolescent 
developmental stage at initiation and initial treatment regime may also explain these findings 
as these individuals may have had poor virological outcomes. LTFU is a marker of poor 
adherence and it was greatest in females who initiated in late adolescence. 
Adolescents who initiated ART in 2010 had less odds of an unsuppressed viral load than 
those who initiated in 2004-2006. In 2004, South Africa initiated the roll-out of ART with a 
lot of recruitment campaigns to identify and initiate as many individuals on ART possible. In 
2008, psychological support in the Hlabisa health sub-district was initiated for those on ART, 
their caregivers and health care workers [51]. This support included provision of  individual 
psychological support for those on ART and training on HIV patient management for health 
care workers [51]. Since 2009, the sub district has benefited from home and mobile 
counselling and testing (HMCT) services and HIV Community Education and Awareness 
campaigns [51]. The adolescents who initiated ART in 2010 may have had increased 
awareness of HIV, its management and the importance of adherence to ART resulting in 
having less likelihood of an unsuppressed viral load compared to those who initiated in 2004-
2006. This further emphasises the reports that good clinical outcomes can be observed despite 
rapid scale up of ART treatment programmes [65, 69]. 
Though the CI was wide, individuals who had a viral load taken > 30 months after ART 
initiation had higher odds of failure compared to those who had it 6-12 months. The small 
number in this category resulted in the wide but significant CI. The individuals who had their 
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viral load done after 30 months had more exposure to ARV drugs which may have resulted in 
drug resistance from an increased risk of poor adherence and hence higher odds of an 
unsuppressed viral load [40]. This indicates the importance of timely viral load monitoring to 
identify those in need of increased adherence support on ART.   
Though not significant, the males had higher odds of an unsuppressed viral load than females 
and this is similar to the association found in children in Uganda [41], this may show that 
males are less adherent to ART than females. The insignificant trend of age in this study 
could echo the reports that as adolescents grow older there is increased independence with 
peer groups becoming important and these factors may reduce adherence to ART and 
therefore an increased odds for an unsuppressed viral load [28]. Unlike in other studies in 
adults and children [41, 42, 44, 45], CD4 cell count was not found to be associated with an 
unsuppressed viral load.  
4.5 Limitations of the study 
This study was a secondary data analysis and did not allow analysis of variables that were not 
collected as part of the programmes patient management. Adherence and prior exposure to 
ART have been found to have important associations with virological failure in previous 
studies and data on these were not available in this study.  
Data was entered into the database through a multiple clerk single entry and this may have 
resulted in erroneous data. The amount of missing data in the analysis was high and this 
could have masked possible associations of some variables with an unsuppressed viral load. 
Of the adolescents eligible for the analysis, 20.7% did not have viral loads. This resulted in a 
low sample size. Imputations of these data would have helped to reduce possible bias.   
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The attrition rate due to death, LTFU and transfer out before 6 months of ART was high and 
may have resulted in survival bias.  
A time-to-event analysis would have been the most appropriate method for investigating the 
factors associated with virological failure in these adolescents but due to the absence of serial 
viral load blood sampling from initiation, this method of analysis was precluded. 
4.6 Generalisability 
The Hlabisa HIV Treatment and Care programme is a decentralised public health programme 
which is in the rural area. It is a nurse/counsellor driven programme with limited physician 
input and is similar to other ART programmes in rural South Africa. The programme has 
additional human resources and infrastructural support from the AC [12] and this may result 
in it differing from other South African DOH programmes. Due to this, caution must be taken 
when generalising the results obtained from this study to other ART programmes.  
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
This study demonstrates that a bimodal distribution of age of adolescents initiating on ART in 
a rural programme in KwaZulu-Natal exists. Mortality rates and LTFU rates in this cohort are 
similar to those of adolescents at other ART programmes in southern Africa and after 
adjusting for adolescent developmental stage and gender, LFTU is greatest in females 
initiating in late adolescence. The prevalence of an unsuppressed viral load after 6 months of 
ART in the adolescents in this study is lower than that of adolescents in other treatment 
programmes and this may indicate better adherence and lower baseline drug resistance in the 
adolescents at the Hlabisa HIV Treatment and Care Programme.  
Significant associations with an unsuppressed viral load in this cohort were the year the 
adolescents initiated ART and the time taken before the first viral load test was done after the 
adolescents initiated ART. Though not significant; males, initiating in late adolescence, 
WHO stage 3/4, prior TB, initiating on NVP containing regimens were associated with 
increased likelihood of an unsuppressed viral load. 
Despite the yearly increase in adolescents initiating ART, good virological responses can be 
obtained through the increased support of both individuals on ART and their health care 
providers. Timely viral load monitoring identifies those in need of increased adherence 
support on ART and may result in good virological responses.   
5.2 Recommendations 
The bimodal distribution of age of adolescents initiating on ART raises the question when 
these individuals were infected by HIV. It has been shown that those infected perinatally and 
sexually have different characteristics and these may influence virological outcomes on ART 
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therefore more research is recommended to answer this question. Females ≥ 15 years of age 
and those initiating whilst pregnant are more likely to become LTFU. This indicates that they 
are an important group of adolescents who need to be targeted by strategies to reduce LTFU 
and hence increase adherence to ART. Further research is recommended in this group to 
investigate factors associated with LTFU.  
Adolescent friendly clinics to manage this cohort are recommended as these individuals have 
different needs to adults or children. This may help improve adherence to treatment and 
therefore result in lower rates of an unsuppressed viral load. Continued HIV awareness and 
treatment campaigns and other psychological support services are also recommended. Viral 
load testing to monitor response to ART is important and should be done early to prevent 
progression to virological failure and drug resistance.  
Further research in this cohort using both qualitative and quantitative methods to understand 
the factors surrounding HIV and its treatment in adolescents is recommended. 
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APPENDICES 
APPENDIX 1: Testing Normality Assumptions 
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APPENDIX 2: Missing data added into the analysis 
 
Variable Missing Found (%) * 
Weight 73 21 (29%) 
WHO stage  182 25 (14%) 
TB treatment  70 28 (40%) 
CD4  28 9 (32%) 
Haemoglobin 120 27(23%) 
Creatinine 122 23 (19%) 
ALT 118 21 (18%) 
Platelets 130 22 (17%) 
Albumin 136 22 (16%) 
Viral load after 6 months 137 45 (33%) 
* Data found in the clinic files and added to the analysis 
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APPENDIX 3: Characteristics associated with adolescents without viral load results 
Characteristics associated with individuals eligible for viral load test with no results 
(n=459) 
Characteristic         without viral load (n=95)             with viral load (n=364) p value 
Age (years) 
Median (IQR) 
10-14 
15-19 
 
 
17 (14-18) 
28       29.5       
67       70.5 
 
13 (11-19) 
221     60.7 
143     39.3 
 
<0.001 
 
<0.001 
Gender 
Females 
Males 
 
 
78       82.1     
17       17.9 
 
219      60.2 
145      39.8 
 
 
<0.001 
WAZ score 
>-2 
≤ -2 
Missing data 
 
 
71      74.7                 
16      16.8    
  8        8.4 
 
249      68.4              
  93      25.6 
  22        6.0 
 
 
 
0.175 
WHO Stage 
Stage 1/2 
Stage 3/4 
Missing data 
 
 
27        28.4             
37       39.0 
31       32.6 
 
  95      26.1             
190      52.2 
  79      21.7 
 
 
 
0.037 
Initiation Clinic 
In DSA 
Not in DSA 
Missing Data 
 
 
40       42.1  
54       56.8  
  1         1.1 
 
145      39.8                            
208      57.1  
  11        3.0 
 
 
0.545 
Prior TB 
No 
Yes 
 
 
74      77.9       
21      22.1       
 
257     70.6       
107     29.4 
 
 
0.158 
On TB treatment 
No 
Yes  
Missing data 
 
 
69      72.6             
16      16.8 
10      10.5 
 
284     78.0              
  69     19.0 
  11       3.0 
 
 
 
0.008 
CD4 cell count  
≤ 100 
101-200 
> 200  
Missing data 
 
 
25       26.3             
44       46.3 
23       24.2        
  3         3.2 
 
110      30.2                    
117      32.1 
127      34.9 
  10        2.8 
 
 
 
 
0.061 
Drug Regime 
EFV containing 
NVP containing 
LPVr containing 
 
 
66       69.5              
29       30.5 
  0         0 
 
292       80.2              
  69       19.0 
    3         0.8 
 
 
 
0.036 
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Year of initiation 
2004-2006 
2007 
2008 
2009 
2010 
 
   
  3        3.2                          
  9        9.5 
13      13.7  
17      17.8     
53      55.8 
   
  43       11.8                         
  53       14.6 
  71       19.5 
  91       25.0 
106       29.1 
 
 
 
 
 
<0.001 
Haemoglobin 
> 7g/dl 
≤ 7g/dl 
Missing data 
 
 
77       81.1                 
  7         7.4  
11       11.6 
 
294       80.8                
  22         6.0     
  48       13.2 
 
 
 
0.835 
Platelets 
>150 000 per µl 
≤150 000 per µl 
Missing data 
 
 
76       80.0              
  7         7.4 
12       12.6 
 
282       77.5              
  23         6.3 
  59       16.2 
 
 
 
0.666 
ALT 
≤60 IU/L 
>60 IU/L 
Missing data 
 
 
81       85.3              
  1         1.1 
13       13.6 
 
308        84.6              
  15          4.1 
  41        11.3 
 
 
 
0.299 
Albumin 
>25 g/L 
≤25 g/L 
Missing data 
 
57       60.0             
23       24.2  
15       15.8 
 
250       68.7                 
  66       18.1    
  48       13.2   
 
 
 
0.265 
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APPENDIX 4: Ethics Clearance 
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APPENDIX 5: Kaplan Meier Estimates 
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Kaplan Meier Estimates of LTFU by Gender and Age Category (p< 0.001) 
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Kaplan Meier Estimates for Overall Mortality 
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Kaplan Meier Estimates of Mortality by Gender and Age category (p=0.145) 
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APPENDIX 6:  Data Use Agreements 
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APPENDIX 7: Change of Research Title Approval 
 
